title: Positioning high-dose radiation in multidisciplinary management of unresectable cholangiocarcinomas: review of current evidence.
abstract: Cholangiocarcinoma is a rare malignancy of the bile ducts. The current standard of care for unresectable nonmetastatic disease is doublet systemic chemotherapy, which provides a median survival of 11.7 months. Although chemoradiation is a therapeutic option that provides almost equivalent or superior survival, the lack of level I evidence presents a major hurdle in routinely recommending it within multidisciplinary clinics. This mini review presents the current evidence on the use of chemoradiation for unresectable nonmetastatic cholangiocarcinoma and rationale for positioning it within multidisciplinary management of unresectable cholangiocarcinomas.
authors.affiliation: Department of Radiation Oncology, Advanced Centre for Treatment Research and Education in Cancer, Tata Memorial Centre, Kharghar, Navi Mumbai, 410 210, India, schopra@actrec.gov.in.
authors.forename: Supriya
authors.initials: S
authors.lastname: Chopra
authors.forename: Ashwathy S
authors.initials: AS
authors.lastname: Mathew
authors.forename: Reena
authors.initials: R
authors.lastname: Engineer
authors.forename: Shyam K
authors.initials: SK
authors.lastname: Shrivastava
mesh_terms: D001650:Bile Duct Neoplasms / Q000628:therapy*; D059248:Chemoradiotherapy / Q000379:methods; D018281:Cholangiocarcinoma / Q000628:therapy*; D019317:Evidence-Based Medicine; D006801:Humans; D015201:Meta-Analysis as Topic; D039781:PubMed; D011879:Radiotherapy Dosage; D016896:Treatment Outcome